News stories about TherapeuticsMD (NASDAQ:TXMD) have trended somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. TherapeuticsMD earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.9908954485922 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- TherapeuticsMD, Inc. (TXMD) stock price is -8.30% down from 50 SMA (analystrecommendation.com)
- May This Data Fuel Up Investor’s Confidence – TherapeuticsMD Inc (NASDAQ: TXMD) (alphabetastock.com)
- Revenue Approximations Analysis: Turquoise Hill Resources Ltd., (NYSE: TRQ), TherapeuticsMD, Inc., (NASDAQ … (globalexportlines.com)
- Is One a Better Investment Than the Other?: Travelport Worldwide Limited, (NYSE: TVPT), TherapeuticsMD, Inc … (globalexportlines.com)
- Notable Stock’s Buzzers: TherapeuticsMD, Inc., (NASDAQ: TXMD), Medtronic plc, (NYSE: MDT); (tradingnewsnow.com)
A number of research firms have recently weighed in on TXMD. Oppenheimer set a $10.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Wednesday, February 21st. BidaskClub lowered shares of TherapeuticsMD from a “sell” rating to a “strong sell” rating in a report on Friday, February 23rd. Cantor Fitzgerald reiterated a “buy” rating and set a $28.00 target price on shares of TherapeuticsMD in a report on Sunday, January 7th. Zacks Investment Research lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Friday, January 12th. Finally, Noble Financial restated a “buy” rating on shares of TherapeuticsMD in a report on Thursday, February 22nd. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. TherapeuticsMD currently has a consensus rating of “Buy” and an average target price of $14.50.
TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings data on Tuesday, February 20th. The company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.01). TherapeuticsMD had a negative return on equity of 63.67% and a negative net margin of 458.49%. The company had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $4.66 million. During the same quarter last year, the business earned ($0.12) earnings per share. The business’s quarterly revenue was down 8.0% on a year-over-year basis. analysts anticipate that TherapeuticsMD will post -0.38 earnings per share for the current fiscal year.
WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact TherapeuticsMD (NASDAQ:TXMD) Share Price” was reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://baseballnewssource.com/2018/03/29/therapeuticsmd-txmd-receiving-somewhat-favorable-news-coverage-study-finds/1970975.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.